Selective L-type, T-type, and nonspecific calcium-channel blockers for stable angina pectoris

American Heart Journal

Volumn 144, Issue 1, 2002, Pages 8-10

  Thadani, Udho ^a  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANTIANGINA PECTORIS AGENT; BEPRIDIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL T TYPE; DILTIAZEM; FELODIPINE; MIBEFRADIL; NIFEDIPINE; NISOLDIPINE; VERAPAMIL;

ANGINA PECTORIS; DOSE RESPONSE; DRUG EFFECT; DRUG FORMULATION; EDITORIAL; HEART ATRIOVENTRICULAR NODE; HUMAN; INOTROPISM; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; VASCULAR SMOOTH MUSCLE;

EID: 0036308584     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2002.122876     Document Type: Article

References (34)

1. Calcium channel antagonists (calcium entry blockers)
2. Calcium-antagonist drugs
3. Treatment of stable angina
4. Choosing the most appropriate treatment for stable angina: Safety considerations
5. Cardiovascular T-type calcium channels: Physiological and pharmacological significance
6. Lack of negative inotropic effects of a new calcium antagonist Ro 40-5967 in patients with stable angina pectoris
7. Effects of the novel T-type calcium channel antagonist mibefradil on human myocardial contractility in comparison with nifedipine and verapamil
8. Medical therapy of stable angina pectoris
9. First line drugs in chronic stable effort angina: The case for newer, long-lasting calcium channel blocking agents
10. Verapamil use in patients with cardiovascular disease: On overview of randomized trials
11. Amlodipine: A once-daily calcium antagonist in the treatment of angina pectoris: A parallel dose response, placebo controlled study
12. Dose response evaluation of once-daily therapy with a new formulation of diltiazem for stable angina pectoris
13. Nifedipine dose-related increase in mortality in patients with coronary heart disease
14. HINT Study. Early treatment of unstable angina in the coronary care unit: A randomized, double-blind placebo controlled comparison of recurrent ischemia in patients trealed with nifedipine or metaprolol or both. Holland Inter-university Nifedipine Trial
15. Double-blind, dose-response, placebo-controlled multicenter study of nisoldipine: A new second generation calcium channel blocker in angina pectoris
16. Meta-analysis of trials comparing β-blockers, calcium antagonists, and nitrates for stable angina
17. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. The PRAISE study
18. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril. V-HeFT III study
19. Comparison of propranolol, diltiazem, and nifedipine in the treatment of ambulatory ischemia in patients with stable angina: Differential effects on ambulatory ischemia, exercise performance, and anginal symptoms
20. Drug therapy: Combined beta-adrenergic and calcium entry blockade in angina pectoris
21. Combined use of calcium channel and beta adrenergic blockers for the treatment of stable angina: Rationale, efficacy and adverse effects
22. Combination therapy for the angina patient
23. Comparative efficacy of 200, 300, and 400 mg of bepridil for chronic, stable angina pectoris
24. Combination propranolol-bepridil therapy in stable angina pectoris
25. Comparative efficacy and safety of bepridil and diltiazem in chronic stable angina pectoris refractory to diltiazem
26. Effects of a new calcium antagonist, mibefradil (Ro 40-5967), on silent ischemia in patients with stable chronic angina pectoris: A multicenter placebo-controlled study
27. Efficacy of mibefradil compared with amlodipine in suppressing exercise-induced and daily silent ischemia
28. Effects of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris: A multicenter, placebo-controlled study
29. Rhabdomyolysis due to interaction of simvastatin with mibefradil
30. Life-threatening interaction of mibefradil and beta-blockers with dihydropyridine calcium channel blockers
31. Effect of mibefradil, a T-type calcium channel blocker, on morbidity and mortality in moderate to severe congestive heart failure: The MACH-1 study
32. Withdrawal of posicor from market
33. Good news far experimental concept but bad news for clinically effective therapy
34. Randomized comparison of T-type versus L-type channel blockade on exercise duration in stable angina: Results of the posicor reduction of ischemia during exercise (PRIDE) trial